Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.8 USD -1.64% Intraday chart for Atossa Therapeutics, Inc. +7.14% +104.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient CI
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors CI
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4 MT
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial CI
Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million. CI
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director CI
Atossa Therapeutics Says Full Enrollment Reached in Karisma-Endoxifen Trial of Breast-Cancer Drug MT
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial CI
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023. CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors CI
North American Morning Briefing : Investors Weigh -2- DJ
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors CI
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group CI
Atossa Therapeutics, Inc. Announces Chief Financial Officer Changes CI
Atossa Therapeutics, Inc. Announces Resignation of Greg Weaver as Executive Vice President CI
Cantor Fitzgerald Starts Atossa Therapeutics at Overweight With $5 Price Target MT
Transcript : Atossa Therapeutics, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023. CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Atossa Therapeutics Gets Regulatory Approval to Conduct Mid-Stage Breast Cancer Therapy in Canada MT
Atossa Therapeutics Regains Compliance With Nasdaq Listing Rule MT
Atossa Therapeutics Enrolls 170 Patients in Phase 2 Karisma-Endoxifen Clinical Trial MT
Chart Atossa Therapeutics, Inc.
More charts
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company's lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.8 USD
Average target price
4.583 USD
Spread / Average Target
+154.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Atossa Therapeutics, Inc. - Nasdaq
  4. News Atossa Therapeutics, Inc.
  5. Atossa Therapeutics : Seeks Shareholder Approval to Expand Authorized Common Shares -- Shares Plunge